Ignite Creation Date:
2024-05-06 @ 3:01 AM
Last Modification Date:
2024-10-26 @ 11:27 AM
Study NCT ID:
NCT02184884
Status:
COMPLETED
Last Update Posted:
2020-05-29
First Post:
2014-06-30
Brief Title:
Effect of Perioperative Clopidogrel Responsiveness on Ischemic Outcome in Patients With Acute Coronary Syndrome Undergoing Off-pump Coronary Artery Bypass Surgery
Sponsor:
Yonsei University
Organization:
Yonsei University
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2020-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The whole blood Thrombelastograph TEG Platelet Mapping assay measures clot strength maximal amplitude MA reflecting maximal platelet function and detects the reduction in platelet function presented as percentage inhibition by both aspirin and clopidogrel A study reported that the TEG can be used as routine monitoring of the variability in ADP receptor inhibition and of antiplatelet therapy Therefore using TEG Platelet Mapping assay we could find out the perioperative clopidogrel responsiveness of the patients with ACS undergoing OPCAB
The purpose of this study is to determine whether the rate of the major adverse cardiac events MACE a combined endpoint of MI revascularization and cardiac death is higher in the patients with high degree of clopidogrel resistance who are scheduled to undergo the OPCAB due to ACS
The purpose of this study is to determine whether the rate of the major adverse cardiac events MACE a combined endpoint of MI revascularization and cardiac death is higher in the patients with high degree of clopidogrel resistance who are scheduled to undergo the OPCAB due to ACS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None